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production as the lab strains A72 and CAI-4. No significant
differences were observed. In past work (4), our investigators
reported quorum-sensing activity in five other laboratory
strains (MEN, SC5314, LGH1095, SG3314, and ATCC10261).
Thus, this study has shown a general theme of farnesol production by the majority of C. albicans strains used here. At this
time we also clarified the distinction between our work, showing that farnesol is the QSM in C. albicans, and that of Oh et
al. (9), who described the production of farnesoic acid as the
QSM in C. albicans 10231. C. albicans 10231 produced no
detectable farnesol (Table 1), thereby revealing a significant
metabolic modification in this strain. To date, C. albicans
10231 is the only strain tested that does not produce farnesol.
Direct comparison of the quorum-sensing activity of farnesoic
acid and farnesol showed that farnesoic acid displays only 3.3%
of the activity exhibited by (E,E)-farnesol (11).
Following our group’s work showing increased farnesol production after treatment of C. albicans with the squalene synthase inhibitor zaragozic acid B (5), additional sterol inhibitors
were studied. Treatment with fluconazole resulted in the doseresponse curve shown in Fig. 1. The farnesol excreted increased roughly 13-fold, reaching a maximum of ca. 1.24 mg of
farnesol per gram (cell dry weight) at 1 M fluconazole (Fig. 1
and Table 2). Intracellular farnesol increased in a proportional
manner (data not shown). The fluconazole concentration
needed for maximal farnesol production (1 M) corresponded
well with the MIC of fluconazole which, for C. albicans A72, is
ca. 1 M, although even at 10 M fluconazole complete inhibition of growth is not achieved. This effect, known as trailing
growth, is common in many strains of C. albicans (6).
Table 2 illustrates the commonality of increased farnesol
production due to sterol inhibition by azole antifungals. Treatment with 1 M ketoconazole, 1 M clotrimazole, or 0.5 M
miconazole led to farnesol production increases of 45-, 45-,
and 44-fold, respectively. Dose-response curves were not conducted for these three azoles. With the doses chosen, very little
growth was observed over 24 h (cell dry weights were ca. 2% of
those of the untreated controls). Therefore, the higher levels of
farnesol produced with clotrimazole, ketoconazole, and miconazole (Table 2) probably reflected how little growth occurred
rather than any mechanistic differences between fluconazole
and the other azoles. Significantly, tolnaftate, an inhibitor of

The inoculum size effect in Candida albicans results from the
natural production and excretion of an extracellular quorumsensing molecule (QSM) which our laboratory identified as
farnesol (4). Exogenous farnesol, purified from spent media or
supplied commercially, prevented mycelial development in
both a growth morphology assay and a differentiation assay.
The differentiation assay used three chemically distinct triggers
for germ tube formation: L-proline, N-acetylglucosamine, and
serum. In all cases, the presence of farnesol prevented the
yeast-to-mycelium conversion, resulting in actively budding
yeasts without influencing cellular growth rates (4). We later
showed that only the (E,E)-isomer of farnesol was biologically
active (11) and that C. albicans cell extracts contained enzymatic activity to convert [3H]farnesyl pyrophosphate (FPP) to
[3H]farnesol (5).
Because FPP is the biosynthetic precursor of both farnesol
(5) and ergosterol (10), we reasoned that drugs which block the
sterol biosynthetic pathway after FPP might lead to the accumulation of FPP which would, in turn, lead to enhanced farnesol production. This reasoning proved correct; treatment of
C. albicans with 0.5 M zaragozic acid B, a potent inhibitor of
squalene synthase (2), led to an eightfold increase in the
amount of farnesol produced by C. albicans (5). At that time
our group predicted that all drugs which blocked carbon flow
through the sterol pathway would also cause enhanced production of farnesol. The present paper tests that generality by
showing that four azole antifungals, fluconazole, clotrimazole,
ketoconazole, and miconazole, also boost farnesol production
by C. albicans. Additionally, because the farnesol-stimulating
activity of zaragozic acid B had only been shown with strain
A72, we tested the generality of farnesol production in C.
albicans by analyzing five other strains, including recent clinical
isolates.
Growth, sample preparation, and determination of extracellular farnesol by gas chromatography-mass spectroscopy were
as previously described (4, 5). Table 1 displays the levels of
extracellular farnesol produced by seven strains of C. albicans.
The four clinical isolates displayed similar levels of farnesol
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The dimorphic fungus Candida albicans excretes farnesol, which is produced enzymatically from the sterol
biosynthetic intermediate farnesyl pyrophosphate. Inhibition of C. albicans by four azole antifungals, fluconazole, ketoconazole, miconazole, and clotrimazole, caused elevated farnesol production (10- to 45-fold). Furthermore, farnesol production occurs in both laboratory strains and clinical isolates (J. M. Hornby et al., Appl.
Environ. Microbiol. 67:2982-2992, 2001) of C. albicans.
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TABLE 2. Enhanced farnesol production by C. albicans A72
treated with drugs which target sterol biosynthesis

TABLE 1. Farnesol production by laboratory and clinical isolates
of C. albicans
Strain of C. albicans

Farnesol produced
(mg/g [dry wt])a

A72....................................................................................... 0.120–0.133
CAI-4................................................................................... 0.120–0.133
ATCC 10231....................................................................... ⬍0.005
Clinical isolate 4b ............................................................... 0.125⫾0.005
Clinical isolate 6................................................................. 0.107⫾0.012
Clinical isolate 11............................................................... 0.137⫾0.003
Clinical isolate 12............................................................... 0.131⫾0.007

squalene epoxidation added as a control because it is known to
be inactive versus C. albicans (1), did not increase farnesol
production above wild-type levels (Table 2).
Our investigators previously proposed the general theme
that inhibition of the sterol pathway would lead to increased
production of farnesol (5). This idea was based on our work
with squalene synthase inhibition by zaragozic acid B (5). This
theme has now been confirmed for the inhibition of lanosterol
14␣-demethylase by four cytochrome P450-inhibitory azoles
(Table 2). For most strains of C. albicans, any drug that inhibits

Farnesol produced
(mg/g [dry wt])

Fold
increase

None
Zaragozic acid (0.5)
Fluconazolec (1)
Clotrimazole (1)
Ketoconazole (1)
Miconazole (0.5)
Tolnaftate (1)

0.120–0.133a
1.0b
1.24
5.44
5.43
5.31
0.132d

8
10
45
45
44

a

From Table 1.
From reference 5.
Fluconazole was kindly provided by Pfizer Pharmaceuticals. Tolnaftate, ketoconazole, clotrimazole, and miconazole were purchased from Sigma. Values
for farnesol production are averages of two independent experiments agreeing
within ⫾ 10%.
d
Value in the presence of tolnaftate is an average of two independent experiments agreeing within ⫾3%.
b
c

a step in the sterol biosynthetic pathway, thus inhibiting carbon
flow to ergosterol, may also increase farnesol production.
Increased farnesol could also be used to screen drugs that
target the sterol biosynthetic pathway and to examine the sensitivity of clinical isolates to known sterol-inhibitory drugs.
While the hypothesis that azoles promote farnesol production
via inhibition of the ergosterol pathway is attractive, at this
time we cannot exclude the possibility that pleiotropic effects

FIG. 1. Increased farnesol production by fluconazole-treated cells. Each point is the average of at least two separate experiments agreeing
within ⫾10%.
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a
Cell dry weights were determined for each sample in Tables 1 and 2. Values
for A72 and CAI-4 are the average of six or more determinations conducted over
a 2-year time span. For C. albicans 10231, no farnesol was detected in two
independent studies (detection limit of 0.005 mg/g).
b
The four clinical isolates examined were randomly chosen from 12 isolates provided by Thomas Stalder (Lincoln,
Nebr.). Values represent the average and variation of duplicate independent measurements.

Antibiotic (concn
[M])
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of the azole family affect farnesol independently of sterol biosynthesis.
Elevated production of farnesol at sublethal levels of fluconazole (Fig. 1), coupled with the known ability of farnesol to
cause a shift from mycelia to yeast in C. albicans (4), provides
an attractive explanation for past work which noted that subinhibitory concentrations of azole drugs inhibited hyphal development and maintained the cells in the yeast morphology.
Interestingly, this inhibitory effect was independent of any inhibition on growth of the fungus (3, 8). Odds (7) also mentioned in his comprehensive review of Candida that “most
azoles are able to prevent or greatly perturb hyphal growth of
C. albicans. The drugs retard or annul the initial outgrowth of
germ tubes and entirely prevent hyphal branching, thus leading
to cultures of largely or entirely yeast-form cells, even on
media that normally support development of long hyphae.”
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